Invest in intelligence that delivers

Spherix Global Insights Appoints Leigh Anne Siino as Chief Revenue Officer

Leigh Anne Siino joins executive team to accelerate company’s revenue growth.  EXTON, PA., June 17, 2024 — Spherix Global Insights, a leading independent market intelligence and advisory firm that delivers commercial value to the global life sciences industry, is proud to announce the appointment of Leigh Anne Siino as Chief Revenue Officer (CRO). In this role, […]

US Gastroenterologists Express Anticipation for Approval of AbbVie’s Skyrizi in Ulcerative Colitis, Projecting Rapid Adoption Post-Launch 

Despite enthusiasm for Skyrizi, key updates for various developmental assets in ulcerative colitis were released at Digestive Disease Week, holding the potential to impact sentiments.   Exton, PA., June 12, 2024 – Despite being the second IL-23 inhibitor to enter the market, AbbVie’s Skyrizi (risankizumab) is expected to have a substantial impact on ulcerative colitis (UC) […]

‘Exciting time’: Biologic use in moderate to severe lupus rose 45% since 2021

Use of biologics to treat moderate to severe systemic lupus erythematosus increased 45% between 2021 and 2023, according to recent findings from a market analysis conducted by Spherix Global Insights. The analysis additionally found that nearly half of moderate-to-severe patients with SLE are currently on a biologic. Meanwhile, among those not currently on a biologic, […]

Leqembi launch hamstrung by physicians’ ‘therapeutic nihilism’

Eisai has recently outlined a range of ways to kick-start Leqembi’s lackluster launch, from increasing the number of neurology account specialists to adding a subcutaneous option. But a Reuters report suggests the company faces a more fundamental problem: Physicians still see Alzheimer’s disease as untreatable. The Japanese drugmaker said 2,000 patients in the U.S. were receiving the amyloid-busting antibody […]

‘Efficacy will lead’ as first-line JAK inhibitor use picks up in moderate to severe UC

Despite a class-wide black box warning for prescribing in the early setting, 31% of providers reported positioning Janus kinase inhibitors as first-line treatment among patients with severe ulcerative colitis, according to survey results. “Where it is positioned in the label today is after an anti-TNF, meaning that patients had to have been on some form of TNF […]

Regeneron and Genentech battle for ophthalmologists’ affinity in Eylea HD, Vabysmo matchup

After seven months on the market, Regeneron’s Eylea HD is already making strides with ophthalmologists. According to Spherix Global Insights’ research, 81% of ophthalmologists who use Eylea HD to treat wet age-related macular degeneration (AMD) are “highly satisfied,” which tracks closely to the 87% who say the same about Roche and Genentech’s Vabysmo, which has […]

Novartis’ Intravenous Formulation of Cosentyx Impacting Prescriber Preferences in Psoriatic Arthritis Treatment, While Pending Launch of UCB’s Bimzelx Poised to Further Disrupt the Market

According to Spherix Global Insights, US rheumatologists are most likely to prefer Bimzelx’s dual IL-17A/F pathway as the most efficacious of all interleukins available in PsA.   EXTON, PA., April 16, 2024 – In October of 2023, the US FDA approved Novartis’ intravenous (IV) formulation of Cosentyx (secukinumab) for the treatment of psoriatic arthritis (PsA), ankylosing […]

Sign up for alerts, market insights and exclusive content in your inbox.

Spherix is excited to announce our expansion into an additional, rapidly evolving specialty market:

HEMATOLOGY

Throughout 2024, we will be publishing over
10 groundbreaking studies covering a wide range of indications within classical hematology.